Age

Any age

Sex

MALE

Healthy volunteers

Not accepted

Prostate cancer patients receiving treatment at Henry Ford Health from the investigator or co-investigator who opt for surgery.
Prostate-specific antigen (PSA) ≤20 ng/mL
Clinical stage ≤cT2
Dominant unilateral lesion with Gleason ≤4+3 on biopsy
No Gleason ≥4 contralaterally
Preoperative SHIM score ≥17 (with or without phosphodiesterase-5 inhibitor use)

• Androgen deprivation therapy within 6 months.
* Nodal positive disease
* Metastatic disease
* Prior prostate cancer therapy (e.g., radiation, HIFU).
* Significant comorbidities precluding surgery or life expectancy \<5 years as defined by the Prostate Cancer Comorbidity Index \[5\].
* Any previous cancer diagnosis.

A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.